Pembrolizumab/Chemo Receives OK From FDA in Advanced Endometrial Cancer

News
Article

Patients with primary advanced/recurrent endometrial carcinoma may now receive pembrolizumab plus chemotherapy as indicated by the FDA.

Results from the phase 3 NRG-GY018 trial (NCT03914612) supported the approval of pembrolizumab plus chemotherapy in this population.

Results from the phase 3 NRG-GY018 trial (NCT03914612) supported the approval of pembrolizumab plus chemotherapy in this population.

Pembrolizumab (Keytruda) plus carboplatin and paclitaxel has been approved by the FDA for patients with primary advanced or recurrent endometrial carcinoma, according to a press release from the agency.1 

Results from the phase 3 NRG-GY018 trial (NCT03914612) led to the approval.2,3 The trial assessed patients with stage III or IVA, stage IVB, or recurrent endometrial cancer, regardless of mismatch repair deficient (dMMR) or proficient (pMMR) disease status.

A total of 810 patients were enrolled, with 588 having pMMR disease and 222 having dMMR disease. Patients were randomly assigned 1:1 to receive either 200 mg of intravenous pembrolizumab every 3 weeks plus 175 mg/m2 of paclitaxel and carboplatin for up to 6 cycles and 400 mg of maintenance pembrolizumab every 6 weeks for an additional 14 cycles, or the same chemotherapy backbone plus placebo and placebo maintenance.

The primary end point was progression-free survival (PFS) in both cohorts. The secondary end points included safety, overall response rate (ORR), duration of response (DOR), and overall survival.

Topline data showed that the median PFS in the pembrolizumab arm for those with dMMR disease was not reached (NR; 95% CI, 30.7-NR) and 6.5 months (95% CI, 6.4-8.7) in the placebo arm (HR, 0.30; 95% CI, 0.19-0.48; P <.00001). The median PFS in the pMMR population was 11.1 months (95% CI, 8.7-13.5) vs 8.5 months (95% CI, 7.2-8.8) in each respective arm (HR, 0.60; 95% CI, 0.46-0.78; P <.0001).

Previous data showed that the ORR in the dMMR population was 82% (95% CI, 72%-89%) for those given pembrolizumab vs 71% (95% CI, 60%-80%) for those given placebo (OR, 1.83; 95% CI, 0.92-3.66). A partial response (PR) rate of 50% vs 55% was observed between arms, and a complete response (CR) rate of 32% vs 15% was also noted.

In the pMMR population, the ORR was 71% (95% CI, 64%-77%) in the pembrolizumab group and 58% (95% CI, 52%-65%) in the placebo group (OR, 1.74; 95% CI, 1.18-2.58). Between each arm, the PR rates were 56% vs 50%, and the CR rates were 15% vs 8%.

The median DOR in the dMMR population was 28.7 months (95% CI, 20.2-NR) in the pembrolizumab cohort vs 6.2 months (95% CI, 4.3-9.2) in the placebo cohort (HR, 0.218; 95% CI, 0.13-0.37; P <.0001). For those in the pMMR population, the median DOR was 9.2 months (95% CI, 7.1-14.7) vs 6.2 months (95% CI, 4.8-6.5) in each respective cohort (HR, 0.467; 95% CI, 0.34-0.64; P <.0001).

The FDA previously granted priority review to pembrolizumab/chemotherapy for this patient population in February 2024.4

References

  1. FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma. News release. June 17, 2024. Accessed June 17, 2024. https://shorturl.at/sZ3Xx
  2. Eskander RN, Sill MW, Beffa L, et al. SEMINAL: Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: the phase 3, NRG GY018 study. 2023 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS). November 5-7, 2023; Seoul, South Korea.
  3. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388:2159-2170. doi:10.1056/NEJMoa2302312
  4. FDA grants priority review to Merck’s application for KEYTRUDA (pembrolizumab) plus chemotherapy as treatment for primary advanced or recurrent endometrial carcinoma. News release. Merck. February 20, 2024. Accessed May 17, 2024. http://tinyurl.com/5hc2vunb
Recent Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.